EVGN vs AMGN vs BIIB vs GILD vs REGN

For growth investors, Evogene Ltd.

(EVGN) is the stronger pick with 50. 9% revenue growth year-over-year, versus 1. 0% for Regeneron Pharmaceuticals, Inc. (REGN). Regeneron Pharmaceuticals, Inc. (REGN) offers the better valuation at 17. 2x trailing P/E (15. 5x forward), making it the more compelling value choice. Analysts rate Amgen Inc. (AMGN) a "Buy" — based on 38 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Regeneron Pharmaceuticals, Inc.

(REGN) is the cheapest at 17. 2x versus Amgen Inc. at 23. 3x. On forward P/E, Biogen Inc. is actually cheaper at 13. 1x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Gilead Sciences, Inc. wins at 0. 12x versus Amgen Inc. 's 5. 04x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Gilead Sciences, Inc.

(GILD) delivered a total return of +117. 0%, compared to -97. 8% for Evogene Ltd. (EVGN). Over 10 years, the gap is even starker: AMGN returned +158. 1% versus EVGN's -99. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Biogen Inc.

(BIIB) is the lower-risk stock at 0. 60β versus Evogene Ltd. 's 1. 32β — meaning EVGN is approximately 119% more volatile than BIIB relative to the S&P 500. On balance sheet safety, Regeneron Pharmaceuticals, Inc. (REGN) carries a lower debt/equity ratio of 9% versus 6% for Amgen Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Evogene Ltd.

(EVGN) is pulling ahead at 50. 9% versus 1. 0% for Regeneron Pharmaceuticals, Inc. (REGN). On earnings-per-share growth, the picture is similar: Gilead Sciences, Inc. grew EPS 1684% year-over-year, compared to -21. 1% for Biogen Inc.. Over a 3-year CAGR, EVGN leads at 109. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Regeneron Pharmaceuticals, Inc.

(REGN) is the more profitable company, earning 31. 4% net margin versus -193. 7% for Evogene Ltd. — meaning it keeps 31. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GILD leads at 39. 7% versus -255. 4% for EVGN. At the gross margin level — before operating expenses — REGN leads at 85. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Gilead Sciences, Inc. (GILD) is the more undervalued stock at a PEG of 0. 12x versus Amgen Inc. 's 5. 04x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Biogen Inc. (BIIB) trades at 13. 1x forward P/E versus 15. 5x for Regeneron Pharmaceuticals, Inc. — 2. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for GILD: 23. 4% to $162. 00.

In this comparison, AMGN (2.

9% yield), GILD (2. 4% yield), REGN (0. 5% yield) pay a dividend. EVGN, BIIB do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Amgen Inc.

(AMGN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 61), 2. 9% yield, +158. 1% 10Y return). Both have compounded well over 10 years (AMGN: +158. 1%, EVGN: -99. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: EVGN is a small-cap high-growth stock; AMGN is a mid-cap quality compounder stock; BIIB is a mid-cap quality compounder stock; GILD is a mid-cap quality compounder stock; REGN is a mid-cap deep-value stock. AMGN, GILD pay a dividend while EVGN, BIIB, REGN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.